𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation

✍ Scribed by Kakkar, A. K.; Balakrishnan, S.

Book ID
121840489
Publisher
SAGE Publications
Year
2014
Tongue
English
Weight
185 KB
Volume
21
Category
Article
ISSN
1078-1552

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Combination therapy with fludarabine and
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network
✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO

Chronic myelogenous leukemia in nonlymph
Chronic myelogenous leukemia in nonlymphoid blastic phase : Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
✍ Stefano Sacchi; Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Mary Beth Rios πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 104 KB πŸ‘ 2 views

## BACKGROUND. The prognoses of patients with chronic myelogenous leukemia in blastic phase (CML-BP) are extremely poor. Treatment of patients with nonlymphoid CML-BP is associated with very low response rates, a median survival of 2-3 months, and significant toxicities. The aim of this study was